Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

 

CURRENTLY ENROLLING STUDIES

HOLLYWOOD NEUROLOGY

For more information, please call: 954-366-0277.

Merck – APECS:   Memory Loss
A two-year study with a new oral drug as a potential disease-modifying therapy in patients 50 to 85 years old who have been experiencing memory loss for a year.

Merck – EPOCH:   Alzheimer’s Disease
A two-year study to evaluate potential disease-modifying therapy (the same medicine as in APECS) in patients 55 to 85 years old with mild to moderate Alzheimer’s Disease.

Merck – 012:   Alzheimer’s Disease
A 6-month study evaluating the effectiveness of a new oral medicine for those patients between 55 and 85 years old and already on a stable dose of Aricept for treating the symptoms of mild to moderate Alzheimer’s Disease.

Roche – MARGUERITE ROAD:   Alzheimer’s Disease
A two-year study with a potential disease modifying treatment given by subcutaneous injection in patients 50 to 90 years old with mild Alzheimer’s Disease.

Toyoma / Alzheimer’s Disease Cooperative Study (UCSD) – NOBLE:
A one-year study to evaluate the neuro-protective effects of a new oral medication in patients who are 55 to 85 years old with mild to moderate Alzheimer’s Disease and on Aricept for at least 6 months with a stable dose for at least 3 months.

Allergan – 127:   Post-Stroke Upper Limb Spasticity
 Botox® Treatment in Adult Patients with Upper Limb Spasticity – A 16-week study evaluating Botox in patients 18 to 80 years old with upper limb spasticity involving the elbow and shoulder due to stroke.

Guerbet – REMIND:   Brain Tumors
A 6-week study evaluating adult patients with known or highly suspected brain tumors that have been detected by previous CT or MRI examination and who are scheduled to undergo a routine contrast-enhanced MRI.  The contrast agent in this study is already FDA approved!

 

HOLLYWOOD PULMONARY

Lead Study Coordinator: Lucy Vargas
954-981-4491 / lvargas@infinityclinicalresearch.com

Forest – ASCENT COPD:   Moderate to Severe COPD with High Cardiovascular Risk
A three-year post-marketing study to evaluate the effect of aclidinium bromide (Tudorza Pressair) on long-term cardiovascular safety and COPD attacks in patients 40 years old or older who are current or former smokers, with moderate to very severe COPD and a history of cardiovascular or cerebrovascular disease and/or significant cardiovascular risk.  This medicine is already FDA approved!

Glaxo SmithKline – IMPACT:   Chronic Obstructive Pulmonary Disease
A one-year study comparing the efficacy, safety and tolerability of  the investigational fixed dose triple combination therapy fluticasone furoate / umeclidinium / vilanterol trifentate (FF / UMEC / VI) compared with one of the FDA approved fixed dose dual combinations of Breo Ellipta (fluticasone furoate / vilanternol), a medicine similar to Advair, and Anoro Ellipta (umeclidinium / vilanterol) a medicine similar to Spiriva plus a fast-acting broncho-dilator; all administered once-daily in the morning with a dry powder inhaler in patients 40 years old or older with chronic obstructive pulmonary disease who are current or former smokers of at least 10 years.

 

PLANTATION CARDIOLOGY

Study Coordinator: Becky Nembhard
954-306-8163 / rnembhard@infinityclinicalresearch.com

Sanofi – ODYSSEY: Recent Acute Coronary Syndrome with Obstructive Coronary Disease
A five-year study comparing a novel new class of drug on the occurrence of cardiovascular events in patients at least 40 years old who have experienced an acute coronary syndrome (ACS) event (unstable angina or heart attack) and despite intensive lipid modifying or statin therapy, are not adequately controlled.

Population Health Research Institute – PALM Registry: Patient Assessment of Lipid Management
One day trial: Patient questionnaire regarding their treatment of cholesterol with single blood draw.

 

SUNRISE NEUROLOGY

Clinical Study Coordinators:
Michele Kroll Fistel, LPN, CCRC; Dalia Ramos, RMA, CCRP; Fanny Gully, CRC; Magdeli Ramos, CCRC

Acorda Therapeutics – MILESTONE: Walk Deficit in Post-Ischemic Stroke
A 20- week long study to determine the effect of two dose strengths of a currently FDA approved Extended Release tablet, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.

Acorda Therapeutics/Civatas- LIDS: Parkinson’s Disease with Levodopa Induced Dyskinesias
A 12-month long study to assess safety and efficacy of a Levodopa Inhalation Powder in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Adamas Pharmaceuticals – EASE LID: Parkinson’s Disease with Levodopa Induced Dyskinesias
A 25-week long study with optional long term extension study testing the Efficacy and Safety of a modified extended-release version of amantadine for the Treatment of Levodopa Induced Dyskinesia in Parkinson’s Disease Patients

Amgen – 20120296 STRIVE: Migraine Prevention
Up to 71-week long study to Evaluate the Efficacy and Safety of an investigation medication in Migraine Prevention
The planned length of participation in the study for an individual subject is up to 71 weeks, which includes the following: Initial screening phase of up to 3 weeks • 4-week baseline phase • 24-week double-blind treatment phase

AstraZeneca – AMARANTH: Early Alzheimer’s Disease
A 24-month long study to evaluate a potential disease modifying therapy, oral formulation, in patients between 55 and 85 years old with early Alzheimer’s disease.

Biogen 109MS414 MITIGATE
An 18-week long study to evaluate whether montelukast can reduce the severity of GI events in subjects taking TECFIDERA® with relapsing forms of MS.

Daiichi Sankyo: Fibromyalgia
A 21-week long study with optional long-term, open label extension to test effectiveness of an investigational drug compared to an FDA approved drug on fibromyalgia pain.

Forum Pharmaceuticals: Mild to Moderate Alzheimer’s disease
A 26-week long study to test effectiveness of two doses of an investigational medication in patients 55-85 years of age, with Mild to Moderate Alzheimer’s disease currently or previously treated with an AChEI (donepezil, rivastigmine, or galantamine).

Lundbeck-STARBEAM: Mild to Moderate Alzheimer’s disease
A 28-week long study with optional long term, open-label extension study in patients with mild-moderate Alzheimer’s disease treated with donepezil as adjunctive therapy for symptomatic treatment of patients with mild-moderate Alzheimer’s disease (AD).

Merck: Mild to Moderate Alzheimer’s disease
A 29-33 week long study to evaluate the potential of an oral investigational medication on improving memory in mild to moderate Alzheimer’s patients, 55-85 years of age, currently taking donepezil.

Novartis – ASSESS: Relapsing-Remitting MS
A one-year study to compare efficacy and safety of 2 doses of oral Fingolimod (Gilenya) to Copaxone in adults at least 18 years old with relapsing remitting multiple sclerosis.

Serono-REDEFINE: Relapsing-Remitting MS
A 10-week long study using REbif® Rebidose® vs. Rebiject II autoinjector in subjects with relapsing remitting multiple sclerosis (RRMS) treated with Rebif®44 mcg subcutaneously three times a week DEFINing patient reported Ease-of-use

Sun Pharma – SPASTICIT Y: Spasticity Due to Ms
A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to multiple sclerosis.

Sun Pharma – SPASTICITY OL: Spasticity Due to MS
A long-term safety study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to MS, who completed 26 weeks of treatment in the spasticity trial.

TransTech Pharma: Mild Alzheimer’s Disease (STEADFAST)
An 18-month long study testing the efficacy and safety of an investigational medication on improving memory in patients with mild Alzheimer’s disease, age 50 and over, and are currently taking AChEI (donepezil, rivastigmine, or galantamine) or memantine.
e.